<SEC-DOCUMENT>0001193125-18-233611.txt : 20180801
<SEC-HEADER>0001193125-18-233611.hdr.sgml : 20180801
<ACCEPTANCE-DATETIME>20180731194335
ACCESSION NUMBER:		0001193125-18-233611
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20180731
ITEM INFORMATION:		Completion of Acquisition or Disposition of Assets
ITEM INFORMATION:		Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20180801
DATE AS OF CHANGE:		20180731

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			MYRIAD GENETICS INC
		CENTRAL INDEX KEY:			0000899923
		STANDARD INDUSTRIAL CLASSIFICATION:	IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835]
		IRS NUMBER:				870494517
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			0630

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-26642
		FILM NUMBER:		18982508

	BUSINESS ADDRESS:	
		STREET 1:		320 WAKARA WAY
		CITY:			SALT LAKE CITY
		STATE:			UT
		ZIP:			84108
		BUSINESS PHONE:		801-584-3600

	MAIL ADDRESS:	
		STREET 1:		320 WAKARA WAY
		CITY:			SALT LAKE CITY
		STATE:			UT
		ZIP:			84108
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>d596171d8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<HTML><HEAD>
<TITLE>Form 8-K</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Washington, D.C. 20549 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>FORM <FONT
STYLE="white-space:nowrap">8-K</FONT> </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>CURRENT
REPORT </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Pursuant to Section&nbsp;13 or 15(d) </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>of the Securities Exchange Act of 1934 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Date of Report (Date of earliest event reported): July&nbsp;31, 2018 </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman" ALIGN="center"><B>MYRIAD GENETICS, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Exact name of registrant as specified in its charter) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="34%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"><B>Delaware</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B><FONT STYLE="white-space:nowrap">0-26642</FONT></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B><FONT STYLE="white-space:nowrap">87-0494517</FONT></B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(State or other jurisdiction</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>of incorporation)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Commission</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>File Number)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(IRS Employer</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Identification No.)</B></P></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>320 Wakara Way </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Salt Lake City, Utah 84108&nbsp;&nbsp;&nbsp;&nbsp; </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Address of principal executive offices) (Zip Code) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Registrant&#146;s telephone number, including area code: (801) <FONT STYLE="white-space:nowrap">584-3600</FONT> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Not Applicable </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Former
name or former address, if changed since last report) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Check the appropriate box below
if the Form <FONT STYLE="white-space:nowrap">8-K</FONT> filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (<I>see </I>General Instruction A.2. below): </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top">Soliciting material pursuant to Rule <FONT STYLE="white-space:nowrap">14a-12</FONT> under the Exchange Act (17 CFR <FONT STYLE="white-space:nowrap">240.14a-12)</FONT> </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="white-space:nowrap">Pre-commencement</FONT> communications pursuant to Rule <FONT STYLE="white-space:nowrap">14d-2(b)</FONT> under the Exchange Act (17 CFR
<FONT STYLE="white-space:nowrap">240.14d-2(b))</FONT> </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="white-space:nowrap">Pre-commencement</FONT> communications pursuant to Rule <FONT STYLE="white-space:nowrap">13e-4(c)</FONT> under the Exchange Act (17 CFR
<FONT STYLE="white-space:nowrap">240.13e-4(c))</FONT> </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether the registrant is an emerging growth company as
defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">Emerging growth company&nbsp;&nbsp;&#9744; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If an
emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange
Act.&nbsp;&nbsp;&#9744; </P> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left"><B>ITEM&nbsp;2.01</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Completion of Acquisition or Disposition of Assets. </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On July&nbsp;31, 2018, Myriad Genetics, Inc. (&#147;Myriad&#148;) completed its acquisition of Counsyl, Inc. (&#147;Counsyl&#148;), in
accordance with the terms of the previously announced Agreement and Plan of Merger (&#147;Merger Agreement&#148;), dated May&nbsp;25, 2018, by and among Myriad, Cinnamon Merger Sub, Inc., a wholly owned subsidiary of Myriad (&#147;Merger
Subsidiary&#148;), Counsyl and Fortis Advisors LLC, as the representative of the securityholders of Counsyl. Pursuant to the terms of the Merger Agreement, Merger Subsidiary was merged with and into Counsyl, with Counsyl continuing as the surviving
corporation and wholly owned subsidiary of Myriad (the &#147;Merger&#148;). </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left"><B>ITEM&nbsp;2.03</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Creation of a Direct Financial Obligation of a Registrant. </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On July&nbsp;31, 2018, Myriad entered into that certain Amendment No.&nbsp;1 (the &#147;Amendment&#148;), by and among Myriad, as borrower, the
lenders party thereto and JPMorgan Chase Bank, N.A., as Administrative Agent (the &#147;Agent&#148;), amending that certain Credit Agreement, dated as of December&nbsp;23, 2016 (the &#147;Credit Agreement&#148;), by and among Myriad, as borrower,
the lenders from time to time party thereto and the Agent. Pursuant to the Amendment, Myriad increased the commitments under its revolving credit facility (the &#147;Facility&#148;) to an aggregate principle amount of up to $350.0&nbsp;million. The
Facility matures on July&nbsp;31, 2023 (the &#147;Maturity Date&#148;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The proceeds of the Facility were used to (i)&nbsp;finance the
acquisition of Counsyl, (ii)&nbsp;pay fees, commissions, transactions costs and expenses incurred in connection with the foregoing, and (iii)&nbsp;for working capital and other general corporate purposes. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Credit Agreement contains customary loan terms, interest rates, and representations and warranties and usual and customary affirmative and
negative covenants, in each case, subject to customary limitations, exceptions and exclusions. The Credit Agreement also contains certain customary events of default. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Facility is secured by a&nbsp;first-lien&nbsp;security interest in&nbsp;substantially&nbsp;all of the&nbsp;assets&nbsp;of Myriad and
certain of its domestic&nbsp;subsidiaries,&nbsp;and&nbsp;each such&nbsp;domestic&nbsp;subsidiary&nbsp;of Myriad&nbsp;has guaranteed the repayment of the Facility. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Agent and its affiliates have various relationships with Myriad and its subsidiaries involving the provision of financial services, such
as investment banking, commercial banking, advisory, paying agent services and escrow services for which they receive customary fees and may do so in the future. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The information contained above under Item&nbsp;2.01 is incorporated herein by reference. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left"><B>ITEM&nbsp;8.01</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Other Events </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On July&nbsp;31, 2018, Myriad issued a press release announcing the completion of the Merger. The press release is attached hereto as Exhibit
99.1 and is incorporated by reference herein. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Cautionary Statement Regarding Forward-Looking Statements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Exhibit 99.1 to this Current Report on <FONT STYLE="white-space:nowrap">Form&nbsp;8-K</FONT> includes &#147;forward-looking statements&#148; as
defined in the Private Securities Litigation Reform Act of 1995.&nbsp;These forward-looking statements reflect current views about future events.&nbsp;Investors should not rely on forward-looking statements because actual results may differ
materially from those predicted as a result of a number of potential risks and uncertainties.&nbsp;These potential risks and uncertainties include, but are not limited to: the possibility that the expected benefits related to the Merger may not
materialize as expected; the risk that sales and profit </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Page 2 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
margins of our molecular diagnostic tests and pharmaceutical and clinical services may decline; risks related to our ability to transition from our existing product portfolio to our new tests,
including unexpected costs and delays; risks related to decisions or changes in governmental or private insurers&#146; reimbursement levels for our tests or our ability to obtain reimbursement for our new tests at comparable levels to our existing
tests; risks related to increased competition and the development of new competing tests and services; the risk that we may be unable to develop or achieve commercial success for additional molecular diagnostic tests and pharmaceutical and clinical
services in a timely manner, or at all; the risk that we may not successfully develop new markets for our molecular diagnostic tests and pharmaceutical and clinical services, including our ability to successfully generate revenue outside the United
States; the risk that licenses to the technology underlying our molecular diagnostic tests and pharmaceutical and clinical services and any future tests and services are terminated or cannot be maintained on satisfactory terms; risks related to
delays or other problems with operating our laboratory testing facilities and our healthcare clinic; risks related to public concern over genetic testing in general or our tests in particular; risks related to regulatory requirements or enforcement
in the United States and foreign countries and changes in the structure of the healthcare system or healthcare payment systems; risks related to our ability to obtain new corporate collaborations or licenses and acquire new technologies or
businesses on satisfactory terms, if at all; risks related to our ability to successfully integrate and derive benefits from any technologies or businesses that we license or acquire; risks related to our projections about our business, results of
operations and financial condition; risks related to the potential market opportunity for our products and services; the risk that we or our licensors may be unable to protect or that third parties will infringe the proprietary technologies
underlying our tests; the risk of patent-infringement claims or challenges to the validity of our patents or other intellectual property; risks related to changes in intellectual property laws covering our molecular diagnostic tests and
pharmaceutical and clinical services and patents or enforcement in the United States and foreign countries, such as the Supreme Court decision in the lawsuit brought against us by the Association for Molecular Pathology et al; risks of new, changing
and competitive technologies and regulations in the United States and internationally; and other factors discussed under the heading &#147;Risk Factors&#148; contained in Item&nbsp;1A of our most recent Annual Report on Form <FONT
STYLE="white-space:nowrap">10-K,</FONT> for the fiscal year ended June&nbsp;30, 2017, which has been filed with the Securities and Exchange Commission, as well as any updates to those risk factors filed from time to time in our Quarterly Reports on
Form <FONT STYLE="white-space:nowrap">10-Q</FONT> or Current Reports on Form <FONT STYLE="white-space:nowrap">8-K.&nbsp;All</FONT> information in the exhibits is as of the date of the exhibits, and Myriad undertakes no duty to update this
information unless required by law. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="12%" VALIGN="top" ALIGN="left"><B>ITEM&nbsp;9.01</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Financial Statements and Exhibits. </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Financial Statements of Business Acquired.</B> </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">The financial statements required by Item&nbsp;9.01(a) will be filed by amendment no later than 71 calendar days after the date this Current
Report on Form <FONT STYLE="white-space:nowrap">8-K</FONT> must be filed. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Pro Forma Financial Information.</B> </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">The pro forma financial information required by Item&nbsp;9.01(b) will be filed by amendment no later than 71 calendar days after the date
this Current Report on Form <FONT STYLE="white-space:nowrap">8-K</FONT> must be filed. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Exhibits.</B> </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD WIDTH="93%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center">Exhibit<BR>Number</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; ">Description</P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>99.1</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Press Release issued by Myriad on July&nbsp;31, 2018.</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Page 3 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><U>EXHIBIT INDEX </U></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD WIDTH="92%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center">Exhibit<BR>Number</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; ">Description</P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>99.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="d596171dex991.htm">Press Release issued by Myriad on July&nbsp;31, 2018. </A></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Page 4 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SIGNATURES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="46%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="2%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="45%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3"><B>MYRIAD GENETICS, INC.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Date: July 31, 2018</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ R. Bryan Riggsbee</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">R. Bryan Riggsbee</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Executive Vice President, Chief Financial Officer</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Page 5 </P>

</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>d596171dex991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.1 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="88%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">


<IMG SRC="g596171ni1.jpg" ALT="LOGO">
</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>News&nbsp;Release</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000">&nbsp;</P></TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="11%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD WIDTH="42%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Media&nbsp;Contact:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Ron&nbsp;Rogers</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Investor&nbsp;Contact:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Scott Gleason</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">(801) <FONT STYLE="white-space:nowrap">584-3065</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">(801) <FONT STYLE="white-space:nowrap">584-1143</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><U>rrogers@myriad.com</U></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><U>sgleason@myriad.com</U></TD></TR>
</TABLE> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Myriad Announces Closing of Counsyl Acquisition </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Transformational Acquisition Enhances Myriad&#146;s Leadership Position in Women&#146;s Health </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>SALT LAKE CITY, July</B><B></B><B>&nbsp;31, 2018 &#150;</B> Myriad Genetics, Inc. (NASDAQ: MYGN), a global leader in personalized medicine, announced today
that it has completed the acquisition of Counsyl, Inc. a leader in reproductive genetic testing based in South San Francisco, Calif. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;We are excited to welcome Counsyl to Myriad and begin the integration process,&#148; said Mark C. Capone, president and CEO of Myriad
Genetics. &#147;This acquisition is an excellent strategic fit and enables us to become the premier Women&#146;s Health organization and a trusted advisor for the highest quality genetic tests.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Myriad will fund the acquisition with a combination of cash, Myriad Genetics common stock and funds from the company&#146;s revolving credit
facility. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Organizational Changes to Expand Capabilities and Facilitate Integration </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As part of the acquisition, Myriad is restructuring its organization to enhance its enterprise capabilities and ensure a seamless integration
process. Rishi Kacker, who previously served as Counsyl&#146;s senior vice president of Technology, will become the new chief technology officer of Myriad Genetics, Inc. In this role, Mr.&nbsp;Kacker will oversee the enterprise-wide technology and
software development functions. Myriad is undergoing a significant strategic initiative to consolidate both its customer facing and internal software systems into a single integrated enterprise-wide system as part of its Elevate 2020 program.
Mr.&nbsp;Kacker will report directly to Mr.&nbsp;Capone in his new role. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Alexander Ford, who previously served as the president of Myriad
Genetic Laboratories Inc., will become the president of the Myriad Women&#146;s Health business unit, which combines the Preventive Care business unit with Counsyl. Eric A. Evans, Ph.D., Counsyl&#146;s chief scientific officer, has accepted a
position as the chief scientific officer of the Myriad Women&#146;s Health business unit. In this role, Dr.&nbsp;Evans will oversee the scientific functions within the subsidiary and report to Mr.&nbsp;Ford. Also reporting to Mr.&nbsp;Ford are other
members of Counsyl&#146;s executive leadership team including Noah Nassar, chief commercial officer; John Tan, senior vice president of operations; and James D. Goldberg, M.D., chief medical officer of Counsyl. </P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Lloyd Sanders, who previously served as the general manager of the Oncology segment, will
become president of the Myriad Oncology business unit which includes the Oncology, Urology and Dermatology segments. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;I am excited
that Counsyl&#146;s executive leadership team will become part of the Myriad organization. Their significant experience will ensure continuity as we integrate our organizations,&#148; said Capone. &#147;We fully expect to leverage their outstanding
leadership and expertise across the entire enterprise as we look for opportunities to accelerate our growth&nbsp;in personalized medicine.&#148; </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About
Myriad Genetics </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Myriad Genetics Inc., is a leading personalized medicine company dedicated to being a trusted advisor transforming
patient lives worldwide with pioneering molecular diagnostics. Myriad discovers and commercializes molecular diagnostic tests that: determine the risk of developing disease, accurately diagnose disease, assess the risk of disease progression, and
guide treatment decisions across six major medical specialties where molecular diagnostics can significantly improve patient care and lower healthcare costs. Myriad is focused on five strategic imperatives: build upon a solid hereditary cancer
foundation, growing new product volume, expanding reimbursement coverage for new products, increasing RNA kit revenue internationally and improving profitability with Elevate 2020. For more information on how Myriad is making a difference, please
visit the Company&#146;s website: <U>www.myriad.com</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Myriad, the Myriad logo, BART, BRAC<I>Analysis</I>, Colaris, Colaris AP, myPath,
myRisk, Myriad myRisk, myRisk Hereditary Cancer, myChoice, myPlan, BRACAnalysis CDx, Tumor BRACAnalysis CDx, myChoice HRD, EndoPredict, Vectra, GeneSight, riskScore and Prolaris are trademarks or registered trademarks of Myriad Genetics, Inc. or its
wholly owned subsidiaries in the United States and foreign countries. <FONT STYLE="white-space:nowrap">MYGN-F,</FONT> <FONT STYLE="white-space:nowrap">MYGN-G.</FONT> </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Safe Harbor Statement </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This press release
contains &#147;forward-looking statements&#148; within the meaning of the Private Securities Litigation Reform Act of 1995, including statements related to: the commencement, timing, and success of the integration process; the acquisition being an
excellent strategic fit and enabling the Company to become the premier Women&#146;s Health genetic testing organization in the world; the manner in which the Company funds the acquisition; the Company&#146;s restructuring of its commercial
organization; Mr.&nbsp;Ford becoming the president of the Myriad Women&#146;s Health business unit; the combination of the Preventive Care business unit with Counsyl; Mr.&nbsp;Sanders becoming the president of the Myriad Oncology
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
business unit which is to include the Oncology, Urology and Dermatology segments; Mr.&nbsp;Kacker becoming the new chief technology officer of Myriad Genetics, Inc. and overseeing the
enterprise-wide technology and software development functions; the Company&#146;s strategic initiative to consolidate both its customer facing and internal software systems into a single integrated enterprise-wide system as part of its Elevate 2020
program; Dr.&nbsp;Evans&#146; position as the chief scientific officer of the Myriad Women&#146;s Health business unit and overseeing the scientific functions; Counsyl&#146;s executive leadership team becoming part of the Myriad organization, and
their significant experience ensuring continuity as the organizations are integrated; the Company&#146;s efforts and expectations for opportunities to accelerate the Company&#146;s growth&nbsp;in personalized medicine; and the Company&#146;s
strategic imperatives under the caption &#147;About Myriad Genetics.&#148;&nbsp;These &#147;forward-looking statements&#148; are based on management&#146;s current expectations of future events and are subject to a number of risks and uncertainties
that could cause actual results to differ materially and adversely from those set forth in or implied by forward-looking statements. These risks and uncertainties include, but are not limited to: the risk that sales and profit margins of our
molecular diagnostic tests and pharmaceutical and clinical services may decline; risks related to our ability to transition from our existing product portfolio to our new tests, including unexpected costs and delays; risks related to decisions or
changes in governmental or private insurers&#146; reimbursement levels for our tests or our ability to obtain reimbursement for our new tests at comparable levels to our existing tests; risks related to increased competition and the development of
new competing tests and services; the risk that we may be unable to develop or achieve commercial success for additional molecular diagnostic tests and pharmaceutical and clinical services in a timely manner, or at all; the risk that we may not
successfully develop new markets for our molecular diagnostic tests and pharmaceutical and clinical services, including our ability to successfully generate revenue outside the United States; the risk that licenses to the technology underlying our
molecular diagnostic tests and pharmaceutical and clinical services and any future tests and services are terminated or cannot be maintained on satisfactory terms; risks related to delays or other problems with operating our laboratory testing
facilities and our healthcare clinic; risks related to public concern over genetic testing in general or our tests in particular; risks related to regulatory requirements or enforcement in the United States and foreign countries and changes in the
structure of the healthcare system or healthcare payment systems; risks related to our ability to obtain new corporate collaborations or licenses and acquire new technologies or businesses on satisfactory terms, if at all; risks related to our
ability to successfully integrate and derive benefits from any technologies or businesses that we license or acquire; risks related to our projections about our business, results of operations and financial condition; risks related to the potential
market opportunity for our products and services; the risk that we or our licensors may be unable to protect or that third parties will infringe the proprietary technologies underlying our tests; the risk of patent-infringement claims or challenges
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
to the validity of our patents or other intellectual property; risks related to changes in intellectual property laws covering our molecular diagnostic tests and pharmaceutical and clinical
services and patents or enforcement in the United States and foreign countries, such as the Supreme Court decision in the lawsuit brought against us by the Association for Molecular Pathology et al; risks of new, changing and competitive
technologies and regulations in the United States and internationally; and other factors discussed under the heading &#147;Risk Factors&#148; contained in Item 1A of our most recent Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT>
for the fiscal year ended June&nbsp;30, 2017, which has been filed with the Securities and Exchange Commission, as well as any updates to those risk factors filed from time to time in our Quarterly Reports on Form
<FONT STYLE="white-space:nowrap">10-Q</FONT> or Current Reports on Form <FONT STYLE="white-space:nowrap">8-K.&nbsp;All</FONT> information in this press release is as of the date of the release, and Myriad undertakes no duty to update this
information unless required by law. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">### </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g596171ni1.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g596171ni1.jpg
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MLL)S$P$  @(! P0" @,! 0     ! !$A,4%187$0@9&Q\*% P2 PT>'Q_]H
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MIZ^RPS]Z'6&!<B91>#ERBY4$3".%,C07M&Q-8K;Q#)L390
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M-YY&]#O2HQWZM=>0 $$+N7AY3QF<KCVW[.-QW;-+UV)3O(6)N%E89DL>N/\
MY/'L4LYV\S5K'CMXP3K!L989A\<Q[';I:;2J*EA,DO>ZA%XZ^?%S 96ME'WZ
MU2M:'T:TFEL6@(UJZAO7*CC3GK&G&0_-3.U#KXZJ9?)E-B=A/Z?IZBZ^^(ZJ
M<=6YR<<I;/MXRK5N?5D?10;ZK6I>I!9"H-@EN3,-5\ BYCSB..XA[?R^4L]O
M+;VQZ?(V[^3VHNNS *RU>KE^>1FAZ#9+B&3Z<S.D^7';:<AF7)[89\Z^87\7
MFLO8JLRRR1\OJ7,W8D,DNMTB:404B$L&!^KAZ<3W!D:F*GL?J5<M=+(MVMC.
MBKU+V2,6Y-J-5]6/BPJ=T3Y\8B,4%P#67>5=8EDKN5H9"W4QPG1?6O78%UC&
MLMS\'J?=G6..V"P^9S>0S5J&_P 6U;EF\\5(^7/.XS(U;/P,79K9. %,+@/'
M;$2/'9>+R=S)O7DEW,I6RYPUIS6/"WCL8[*<O??C+Q :M_Z1>WS&>,K4*V[*
M,JC0-V<#)9&]C\FUP-U)2<C$'C,@.S6Q7#W!W#QW7B:UG+:9G(9_)8W*B3NI
MAJ.$<^,E0KM\42X4(]-'^_+3PXI7ZU?-G@NVPQU3,35$?0W)R:@^<.MP30L,
M9AZSDFN0 ]#W\=Y(9>[A.O7N5JU'?G\U[E9N*H73].<V]=9M'/OQS_#X<N.R
M2G)WE3D[!6,L_+Y_/55DSY2\H%]VL;;E8)<,3"XT"3XQ+L==MKQ2:?:(-RE;
M+9=U:D-N_=%]F*?Z/,)N=(4L98]X(.#GS^B:Y8W 8WM?)UE;,MZA-7*Y'N,R
MY5)KZAZHB2,^4EI'CY?R?#CPXUD8_LCZ-./47</C+ECE\>U0JO;[OW?B-41\
MN!6E8*6$;06 P  ,> B(Q$#$<:3QIMCE]D<:;8T^K2-/[./".--/#P\.7$SI
M'/QGSGV_7QX>''*(CV<>''AQX<::1_9QX<<N*WK/E/S7U,_PK\UZ.W^)>@WY
M=Z7J_P#F-_U<]->*'S/I_,O1U_F'2_1>MZ0>JZ>G+9UM=/L_I/\ _]H " $!
M P$_(?77CWED&<U#R6=)L# JQ_&!;#I;0&!7X"/X>+65@G'9B/"S*AYQ)!>(
M;5\+4"% <(NF1?#HE-)EF]I?X=G#Z= "9(XI*FT6)?I(":UM$*$N)=71JRTN
M7#*""/+?R'SZRAZ&>5YNP"Y!&!2!C5NAI=KE?]?!UE< ;0 X!S(\GQX_R%T=
MR5N>1#T@10PM(ZQWR(&]1JV[E(=C1FU02].1B0*8KPSCGR2]K WP2T15UQT[
MUO$F!3#!4OLRD&^LN4[^EP;:SZ-S$$6_BYK?@[S5Y@HJ5_BXK>SURQ'1V H(
M]-Y5;@LA( 2&BB4Y(,E#I<S*SG[*D>380&;%F0J8QO.Z70]!RN%%H%,E='7/
M8H5G40%9.D\*0-@,N;;16,LZS<&3MFMNJ93B),[<B)2&00X/#0:Z"MM?FJ]F
M.".)'6WD.0F5HMI#(2YRMJFD;@E7P.IM1N*Y?Y'^^4O!T(12&*S$;5>H4A4-
M1W)ULE:KOPAER/V55?[NH8Z5A*A@&J*BNJCTWPQPTYH[@-;B4MUSUNW;'R3,
MKA$577HO=@0K9J5!G11C'=+PX&N+<XZ19PA_A #=Y0I.[TJ0KA>O 1'#"V_8
MVRK>3[4*0(U$S)V_!8+@L91(B!-8EHMN5R^@(<5["\:B\BM!#:OJ6. ;[Q9$
M<O':[+\<M02'6ZV.\/:<+@H)(T+0=IB%X[RZ@PH/,%YM.$):P._=7,G?;J+E
M&W=="&"/ZAL' 8(%0!6>8 '>-)1QZ'&^:S08^=+<KI_='5[GD/=B""'![^,1
M65W0VX+\7JU@/&(8!0KP2:V@"_,)>FRS@0S['5&^I7FB/;T))LR.A. !8XM1
M^1%C2QQ=3@4I+,[IN79:K+%8K_*%?5%3^DRFAJGS$1)A0)T8<QC(&E@;)ZKT
MA %M4)XM'%WD_P =8&=<I5V#-0T%;Q<&J[2ZQ4(H%5UP3<+S-CIR,!H$UOVP
M%M0EW4=D<O(2I3W(,VZRU]--DV5SI69P(1%ME5(\EX3Q&\;J7Z14<$&;IX#Q
M2*R_QLT2!ZHK'LC$3GI>!I":CV'O'B%W>4,/ICU0=,"E>5\,OY-9*]%IXX(8
M"G.W!M .+(H.#=*30.V[9T[=>TNE=L!<(N#P7.'Q''A2E'W2B2ZA4K8"RL<6
MH/6!S<.<,D-Z#S U4J?3BFVW-^AQ&1-D%< >C^$/?QK6<)5* B D?)=+5O'+
MOE,%2DMJ(=6LIT1L*3: 12MMVPB ).S"D[L1/$582GEO-PZKX&@^A3DT,\$Q
MK*:;F@% "1LI1(E463&LH,>=!OH,U%1+\1&4XQ]K.&M,BM&A,XHRW@<G;Z#M
MJ 3((MPKB)J#UCNQDFK!N9OVD/LJ%MIL(J --QGX\-"Y(8$>MARU4+!S&)"!
MD]M)7=RC!(-=*",++1LO4*.13\F<QAJ%,QAYC$+<E<8L,&9ZW9E!S$Q5RBPM
M)#&<=N-L4!K6T>M0%5"X%$:.!(6UUYC 75Q%2B\F0IAVVR(LGYI8UQ8V09F)
MK-@1N<,P6AX%.$50Z8DT.8W7YMU7#M$B;NMSI=DFIH;:BA+1UEW 1R51<"V7
M\DPV1B'BIK0AW:UOW^'F9X#4LEX4!R#H&1UZ0QZ(VS*.'P?E2S8^#_FXV II
M63PIB9KKZXX@ PP% 34]. Q0P(Z+HA8 ^!4&* " H".QBX6 4& .@503.=_=
MY^44SV[&N.GCM,0#6B@4Z 8F $NP 0TKD37[';QTQ+X-;4 6NUK:SL.>#G/W
M.S_.THT#N%9B83!H0AX$Q.V354572ND!HJ?BEUWKU\5/CRO_  E_'#^3_]H
M" $" P$_(?7]DRC &B'9_BV;X@-H"46Z7LL-IXE%*5WMU0EN0G+XA)"K:^>?
MX=CZ4*\PC=$+OEJ:::T.>V<^TQ5O#"\H7@KLMR9G):/]6O1PW_GN8?0G>0NE
MQM"N<>T5BO>.7+?(7E)0BO<[32..YYW+Q;B%.25SZ(;8(Z?3HE^S*K_*KFSZ
M95;E7$&O,,M:H%U9?Z0'TZKH'?O+Q#Q!!Z%VW<I:8I%;@+$)H^2#7UENGF,.
M28Z!-*DYZXQ-Z)4N<$[TW_R6CZ+',NO%(B+RAG>53*FHH,>*6Z(?2]C@)@2C
M!%/EO7>#4OI?:/\ I6BU<W>G](F5KCWBZ0+Y:EZ[S7>&CS'_ (0,)FC%8ZW!
M4<+_ )*LC?5XZ/U#*U;<'R4*''I JH@6J3>K[3;*#7/HX:;COTPIAUAKXJF5
M9?1^V_3/WOH?[]"/O?<X>3T0:AA<00GA"&N577TU^,Y]#DQH&\XG83"A*='U
M$D4.HJ+25XW J#;3M#*E-*8_4Y>G1W670=<>"H%):#\9)AU@JS4,"&![%3S&
MXPM(P5N^)8:JW^HU":3G69R2&GCCD,H0I,0,Q)8PQJ;@(B@X)DV;)4@K\?\
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M)#A6:J46*:^:B_4L^F^'.,W+K]!GX@+).K^DL:A=B%;1:'<_]B>,&AC.2 S
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MV%D>#T_(\+.#U_AO[GY[DOMANSI?L^R:>'VA,C6I.G!ZMS785$3"D8\1D=6
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MQ*X(P,7@?$<% ZE!:VP9E ($.$['7^%K<, <^B3?%_\ DN&8!1P-6OQMXB%
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%?;^3_]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
